<DOC>
	<DOCNO>NCT02441829</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics ( PK ) , safety , tolerability single oral dose eleclazine metabolite , GS-623134 , participant normal impaired renal function . Participants healthy control group match participant impaired renal function age ( ± 5 year ) , gender , body mass index ( ± 10 % ) .</brief_summary>
	<brief_title>Pharmacokinetics Eleclazine Adults With Normal Impaired Renal Function</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Long QT Syndrome</mesh_term>
	<criteria>All Individuals : Be nonsmoker consume &lt; 20 cigarette per day Have calculate body mass index ( BMI ) 18 36 kg/m^2 , inclusive , study screen Have either normal 12lead electrocardiogram ( ECG ) one abnormality consider clinically insignificant investigator Screening lab within defined threshold Individuals mild , moderate , severe renal impairment must also meet follow additional inclusion criterion eligible participation study : Must diagnosis chronic ( &gt; 6 month ) , stable renal impairment clinically significant change within 3 month ( 90 day ) prior study drug administration ( Day 1 ) Individuals severe renal impairment , creatinine clearance ( CLcr ) must 1529 mL/min , inclusive ( use CockcroftGault method ) base serum creatinine actual body weight measure screen evaluation . If individual 's score change course study , score screening use classification . Individuals moderate renal impairment , CLcr must 3059 mL/min , inclusive ( use CockcroftGault method ) base serum creatinine actual body weight measure screen evaluation . If individual 's score change course study , score screening use classification . Individuals mild renal impairment , CLcr must 6089 , inclusive mL/min ( use CockcroftGault method ) base serum creatinine actual body weight measure screen evaluation . If individual 's score change course study , score screening use classification . Individuals normal renal function must also meet follow additional inclusion criterion eligible participation study : Must , opinion Investigator , good health base upon medical history , physical examination , vital sign , screen laboratory evaluation Must CLcr ≥ 90 mL/min ( use CockcroftGault method ) base serum creatinine actual body weight measure screen evaluation . History meningitis encephalitis , epilepsy , seizure , migraine , tremor , myoclonic jerk , narcolepsy , obstructive sleep apnea , anxiety , syncope , head injury family history seizure Presence history cardiovascular disease ( include history myocardial infarction base ECG and/or clinical history , history ventricular tachycardia , congestive heart failure , cardiomyopathy , leave ventricular ejection fraction &lt; 40 % ) , cardiac conduction abnormality , family history Long QT Syndrome , unexplained death otherwise healthy individual age 1 30 year Syncope , palpitation , unexplained dizziness Implanted defibrillator pacemaker Medical history renal carcinoma hepatorenal syndrome . Individuals receive anticipate use hemodialysis , peritoneal dialysis , renal replacement therapy medical procedure serve surrogate renal function study . Individuals fluctuate rapidly deteriorate renal function . Assessment stability individual 's renal function determine investigator . Renal allograft recipient Experienced hypertensive crisis , require addition ≥1 antihypertensive drug , require intensive antihypertensive therapy ( eg , addition new drug class ) last 3 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>Renal Impairment</keyword>
</DOC>